MedTrace Logo

Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients

NCT04673422 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 358

Last updated 2023-07-18

No results posted yet for this study

Summary

This study aims to determine the efficacy of montelukast in reducing the incidence of dengue warning signs in adult dengue patients.

Conditions

  • Dengue
  • Dengue With Warning Signs
  • Dengue Shock Syndrome

Interventions

DRUG

Montelukast

A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter

DRUG

Placebo

A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter

Sponsors & Collaborators

  • Phramongkutklao College of Medicine and Hospital

    lead OTHER

Principal Investigators

  • Worapong Nasomsong, MD · Phramongkutklao College of Medicine and Hospital

  • Worayon Chuerboonchai, MD · Ananda Mahidol Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2023-06-17
Completion
2023-06-17

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04673422 on ClinicalTrials.gov